GTHP News Alert Guided Therapeutics (GTHP) 0.2000 01/25/2015
Post# of 273250
Posted On: 01/25/2015 1:32:41 AM
Guided Therapeutics (GTHP) 0.2000 $GTHP
Cervical Cancer Diagnostic Tests Market - 2014 Global Industry Analysis
M2 - Tue Dec 16, 5:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/q8j6pp/cervical_cancer) has announced the addition of the "Cervical Cancer Diagnostic Tests Market - Global Industry Analysis, Size, Share, Growth, Trends" report to their offering. The global cervical cancer diagnostic tests market is segmented based on types of tests performed for the diagnosis of cancer patients. Based on the test types, the market is segmented into Pap smear tests, HPV testing, colposcopy, endocervical curettage procedure and others, which comprise cone biopsy and Loop Electrosurgical Excision Procedure (LEEP). Market size estimates and forecasts for the period 2012 to 2020 have been provided for each of the segments mentioned above in terms of USD million, considering 2013 as the base year for calculating market forecast and 2012 as the historical year. The CAGR (%) of each market segment for the forecast period 2014 to 2020 has also been provided along with market size estimations. Geographically, the global cervical cancer diagnostic tests market has been segmented into four major regional markets: North America, Europe, Asia Pacific and Rest of World (RoW). The market size estimations and forecasts for the period 2012 to 2020 have been provided for each of these regions at a segment level, in terms of USD million along with the CAGR for the forecast period 2014 to 2020. This study further offers market recommendations for the global cervical cancer diagnostic tests market. These include factors that may play a critical role in enhancing or boosting the market in the near future, as well as steps that need to be considered to ensure success for manufacturers. Key players profiled in this report include Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics, Inc., QIAGEN N.V., Femasys, Inc., Zilico Ltd., Guided Therapeutics, Inc., OncoHealth Corp., Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Cervical Cancer Diagnostic Tests Market, by Type of Test Chapter 5 Global Cervical Cancer Diagnostics Tests Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles For more information visit http://www.researchandmarkets.com/research/q8...cal_cancer
DGX: 70.89 (-1.12), QGEN: 23.55 (-0.02), HOLX: 29.34 (-0.17)
Clinical Results Presented at Turkish Medical Congress Further Support LuViva(R) Advanced Cervical Scan for Primary Screening and Detection of Cervical Cancer
Business Wire - Thu Dec 04, 7:06AM CST
The LuViva(R) Advanced Cervical Scan continues to demonstrate the capability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods, according to recent studies presented at the 25th Turkish Society of Gynecology Oncology Congress.
Guided Therapeutics prices USD3.8m public offering of common stock and warrants
M2 - Thu Nov 27, 5:47AM CST
Biophotonic technology company Guided Therapeutics (OTC:BBGTHP) stated on Wednesday that it expects to raise gross proceeds (including non-cash extinguishment of debt) of approximately USD3.8m from public offering of common stock and warrant.
Guided Therapeutics prices offering
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 9:52AM CST
Guided Therapeutics Announces Pricing of $3.8 Million Public Offering
Business Wire - Wed Nov 26, 9:20AM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of approximately 16.8 million shares of its common stock, and warrants to purchase shares of its common stock, for gross proceeds to the Company (including non-cash extinguishment of debt) of approximately $3.8 million. The shares and warrants are being offered at a combined price of $0.225 per share. Each warrant will be exercisable for five years to purchase one half of a share of the Company's common stock at an exercise price of $0.225 per share.
Nigerian Clinical Studies Demonstrate Advantages of LuViva(R) Advanced Cervical Scan for Screening and Detecting Cervical Pre-Cancer in Africa
Business Wire - Wed Nov 19, 7:05AM CST
Results of two clinical studies of the LuViva(R) Advanced Cervical Scan showed the versatility of the technology in its ability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods. The studies were presented at the Society of Gynecology and Obstetrics of Nigeria 2014 conference in Asaba, Nigeria, this week.
Guided Therapeutics' (GTHP) CEO Gene Cartwright on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 3:24PM CST
Guided Therapeutics Reports Third Quarter 2014 Results
Business Wire - Thu Nov 13, 3:49PM CST
--Product Sales up 30% Sequentially from Second Quarter
Guided Therapeutics reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:42AM CST
Guided Therapeutics to Report Third Quarter 2014 Results and Hold Conference Call
Business Wire - Thu Nov 06, 7:01AM CST
Guided Therapeutics, Inc. (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its third quarter ended September 30, 2014 on Thursday, November 13, 2014, after the market closes.
US Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Tue Sep 30, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nqkj8f/us_sales_and) has announced the addition of the "US Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This unique report provides US sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Companies Mentioned: Partial List - Diagnocure - Diasorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio For more information visit http://www.researchandmarkets.com/research/nq..._sales_and
SQNM: 3.62 (-0.10), MYGN: 36.20 (-0.58), ENZ: 3.47 (-0.02), DGX: 70.89 (-1.12), HOLX: 29.34 (-0.17)
Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Tue Sep 30, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwszsk/sales_and_market) has announced the addition of the "Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This new report provides sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Companies Featured (Partial List) - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - DiaSorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech For more information visit http://www.researchandmarkets.com/research/mw...and_market
MYGN: 36.20 (-0.58), ENZ: 3.47 (-0.02), A: 38.81 (-0.84), CPHD: 55.02 (-0.33), DHR: 84.14 (-0.36), HOLX: 29.34 (-0.17)
Guided Therapeutics Announces Initial $200,000 Investment from Turkish Distributor, ITEM Medical Technologies Group
Business Wire - Mon Sep 08, 7:40AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that its Turkish distributor, ITEM Medical Technologies Group, referred to as ITEM, has committed to invest $200,000 in a private placement of Guided Therapeutics' common stock.
Guided Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10th
Business Wire - Thu Sep 04, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) developer of the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, today announced that it will be a featured presenter at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the New York Palace Hotel in New York City.
Guided Therapeutics Initiates Cervical Cancer Screening Trial for LuViva(R) Advanced Cervical Scan
Business Wire - Tue Aug 19, 7:02AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it will begin enrollment this week in a multi-center clinical trial to expand claims for the LuViva(R) Advanced Cervical Scan to include front-line screening for cervical cancer.
Guided Therapeutics Reports Second Quarter 2014 Results
Business Wire - Wed Aug 13, 3:07PM CDT
--Submitted amended PMA for LuViva(R) Advanced Cervical Scan
Guided Therapeutics to Report Second Quarter 2014 Results and Hold Conference Call
Business Wire - Thu Jul 31, 2:11PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its second quarter ended June 30, 2014 on Wednesday, August 13, 2014, after the market closes.
Guided Therapeutics Files PMA Amendment with FDA for LuViva(R) Advanced Cervical Scan
Business Wire - Fri Jul 25, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has filed an amendment to its premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the LuViva(R) Advanced Cervical Scan.
Guided Therapeutics Granted Additional Key Patent for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Jul 17, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that U.S. Patent and Trademark Office granted a new patent with 22 claims that support the technology behind the LuViva(R) Advanced Cervical Scan.
Guided Therapeutics' LuViva(R) Advanced Cervical Scan Awarded Mexican Regulatory Approval
Business Wire - Thu Jul 10, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that LuViva(R) Advanced Cervical Scan was approved for sale in Mexico by the Federal Commission for Protection against Health Risks (COFEPRIS).
Cervical Cancer Diagnostic Tests Market - 2014 Global Industry Analysis
M2 - Tue Dec 16, 5:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/q8j6pp/cervical_cancer) has announced the addition of the "Cervical Cancer Diagnostic Tests Market - Global Industry Analysis, Size, Share, Growth, Trends" report to their offering. The global cervical cancer diagnostic tests market is segmented based on types of tests performed for the diagnosis of cancer patients. Based on the test types, the market is segmented into Pap smear tests, HPV testing, colposcopy, endocervical curettage procedure and others, which comprise cone biopsy and Loop Electrosurgical Excision Procedure (LEEP). Market size estimates and forecasts for the period 2012 to 2020 have been provided for each of the segments mentioned above in terms of USD million, considering 2013 as the base year for calculating market forecast and 2012 as the historical year. The CAGR (%) of each market segment for the forecast period 2014 to 2020 has also been provided along with market size estimations. Geographically, the global cervical cancer diagnostic tests market has been segmented into four major regional markets: North America, Europe, Asia Pacific and Rest of World (RoW). The market size estimations and forecasts for the period 2012 to 2020 have been provided for each of these regions at a segment level, in terms of USD million along with the CAGR for the forecast period 2014 to 2020. This study further offers market recommendations for the global cervical cancer diagnostic tests market. These include factors that may play a critical role in enhancing or boosting the market in the near future, as well as steps that need to be considered to ensure success for manufacturers. Key players profiled in this report include Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics, Inc., QIAGEN N.V., Femasys, Inc., Zilico Ltd., Guided Therapeutics, Inc., OncoHealth Corp., Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Cervical Cancer Diagnostic Tests Market, by Type of Test Chapter 5 Global Cervical Cancer Diagnostics Tests Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles For more information visit http://www.researchandmarkets.com/research/q8...cal_cancer
DGX: 70.89 (-1.12), QGEN: 23.55 (-0.02), HOLX: 29.34 (-0.17)
Clinical Results Presented at Turkish Medical Congress Further Support LuViva(R) Advanced Cervical Scan for Primary Screening and Detection of Cervical Cancer
Business Wire - Thu Dec 04, 7:06AM CST
The LuViva(R) Advanced Cervical Scan continues to demonstrate the capability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods, according to recent studies presented at the 25th Turkish Society of Gynecology Oncology Congress.
Guided Therapeutics prices USD3.8m public offering of common stock and warrants
M2 - Thu Nov 27, 5:47AM CST
Biophotonic technology company Guided Therapeutics (OTC:BBGTHP) stated on Wednesday that it expects to raise gross proceeds (including non-cash extinguishment of debt) of approximately USD3.8m from public offering of common stock and warrant.
Guided Therapeutics prices offering
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 9:52AM CST
Guided Therapeutics Announces Pricing of $3.8 Million Public Offering
Business Wire - Wed Nov 26, 9:20AM CST
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of approximately 16.8 million shares of its common stock, and warrants to purchase shares of its common stock, for gross proceeds to the Company (including non-cash extinguishment of debt) of approximately $3.8 million. The shares and warrants are being offered at a combined price of $0.225 per share. Each warrant will be exercisable for five years to purchase one half of a share of the Company's common stock at an exercise price of $0.225 per share.
Nigerian Clinical Studies Demonstrate Advantages of LuViva(R) Advanced Cervical Scan for Screening and Detecting Cervical Pre-Cancer in Africa
Business Wire - Wed Nov 19, 7:05AM CST
Results of two clinical studies of the LuViva(R) Advanced Cervical Scan showed the versatility of the technology in its ability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods. The studies were presented at the Society of Gynecology and Obstetrics of Nigeria 2014 conference in Asaba, Nigeria, this week.
Guided Therapeutics' (GTHP) CEO Gene Cartwright on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 3:24PM CST
Guided Therapeutics Reports Third Quarter 2014 Results
Business Wire - Thu Nov 13, 3:49PM CST
--Product Sales up 30% Sequentially from Second Quarter
Guided Therapeutics reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:42AM CST
Guided Therapeutics to Report Third Quarter 2014 Results and Hold Conference Call
Business Wire - Thu Nov 06, 7:01AM CST
Guided Therapeutics, Inc. (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its third quarter ended September 30, 2014 on Thursday, November 13, 2014, after the market closes.
US Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Tue Sep 30, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nqkj8f/us_sales_and) has announced the addition of the "US Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This unique report provides US sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Companies Mentioned: Partial List - Diagnocure - Diasorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio For more information visit http://www.researchandmarkets.com/research/nq..._sales_and
SQNM: 3.62 (-0.10), MYGN: 36.20 (-0.58), ENZ: 3.47 (-0.02), DGX: 70.89 (-1.12), HOLX: 29.34 (-0.17)
Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country
M2 - Tue Sep 30, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwszsk/sales_and_market) has announced the addition of the "Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country" report to their offering. This new report provides sales and market share estimates for major suppliers of cancer diagnostic testing products by assay and country. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Companies Featured (Partial List) - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - DiaSorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech For more information visit http://www.researchandmarkets.com/research/mw...and_market
MYGN: 36.20 (-0.58), ENZ: 3.47 (-0.02), A: 38.81 (-0.84), CPHD: 55.02 (-0.33), DHR: 84.14 (-0.36), HOLX: 29.34 (-0.17)
Guided Therapeutics Announces Initial $200,000 Investment from Turkish Distributor, ITEM Medical Technologies Group
Business Wire - Mon Sep 08, 7:40AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that its Turkish distributor, ITEM Medical Technologies Group, referred to as ITEM, has committed to invest $200,000 in a private placement of Guided Therapeutics' common stock.
Guided Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10th
Business Wire - Thu Sep 04, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) developer of the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, today announced that it will be a featured presenter at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the New York Palace Hotel in New York City.
Guided Therapeutics Initiates Cervical Cancer Screening Trial for LuViva(R) Advanced Cervical Scan
Business Wire - Tue Aug 19, 7:02AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it will begin enrollment this week in a multi-center clinical trial to expand claims for the LuViva(R) Advanced Cervical Scan to include front-line screening for cervical cancer.
Guided Therapeutics Reports Second Quarter 2014 Results
Business Wire - Wed Aug 13, 3:07PM CDT
--Submitted amended PMA for LuViva(R) Advanced Cervical Scan
Guided Therapeutics to Report Second Quarter 2014 Results and Hold Conference Call
Business Wire - Thu Jul 31, 2:11PM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its second quarter ended June 30, 2014 on Wednesday, August 13, 2014, after the market closes.
Guided Therapeutics Files PMA Amendment with FDA for LuViva(R) Advanced Cervical Scan
Business Wire - Fri Jul 25, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has filed an amendment to its premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the LuViva(R) Advanced Cervical Scan.
Guided Therapeutics Granted Additional Key Patent for LuViva(R) Advanced Cervical Scan
Business Wire - Thu Jul 17, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that U.S. Patent and Trademark Office granted a new patent with 22 claims that support the technology behind the LuViva(R) Advanced Cervical Scan.
Guided Therapeutics' LuViva(R) Advanced Cervical Scan Awarded Mexican Regulatory Approval
Business Wire - Thu Jul 10, 7:05AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that LuViva(R) Advanced Cervical Scan was approved for sale in Mexico by the Federal Commission for Protection against Health Risks (COFEPRIS).
(0)
(0)Scroll down for more posts ▼